Sunshine Heart to Release Fourth Quarter and Year-End 2013 Results on March 11, 2014
February 26 2014 - 12:27PM
Sunshine Heart, Inc. (Nasdaq:SSH) today announced that its fourth
quarter and year-end 2013 results will be released on Tuesday,
March 11, 2014, before the open of the stock market. The company
will host a conference call and webcast at 9:00 AM ET that morning,
during which management will discuss the company's financial
results and provide a general business overview.
To access the live webcast, please visit the Investors page of
the Sunshine Heart website at http://ir.sunshineheart.com.
Alternatively, you may access the live conference call by dialing
(877) 303-9826 (U.S.) or (224) 357-2194 (international) and using
conference ID 3021959. An audio archive of the webcast will be
available following the call at http://ir.sunshineheart.com.
About the C-Pulse® Heart Assist System The
C-Pulse Heart Assist System, or C-Pulse System, an investigational
device in the United States, Canada and countries that do not
recognize the CE mark approval, utilizes the scientific principles
of intra-aortic balloon counterpulsation applied in an extra-aortic
approach to assist the left ventricle by reducing the workload
required to pump blood throughout the body, while increasing blood
flow to the coronary arteries. Combined, these potential benefits
may help sustain the patient's current condition or, in some cases,
reverse the heart failure process, thereby potentially preventing
the need for later-stage heart failure devices, such as left
ventricular assist devices (LVADs), artificial hearts or
transplants. It may also provide relief from the symptoms of Class
III and ambulatory Class IV heart failure and improve quality of
life and cardiac function. Based on the results from our
feasibility trial, we also believe that some patients treated with
our C-Pulse System will be able to stop using the device due to
sustained improvement in their condition as a result of the
therapy. Caution: Investigational device, limited by Federal (or
United States) Law to Investigational use. About Sunshine®
Heart
Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical
device company focused on developing, manufacturing and
commercializing the C-Pulse System for treatment of Class III and
ambulatory Class IV heart failure. Sunshine Heart has
completed an approved U.S. Food and Drug Administration (FDA)
feasibility clinical trial of the C-Pulse System and presented the
results in November 2011. In March 2012, the FDA notified
the Company that it could move forward with an investigational
device exemption (IDE) application. Sunshine Heart received
unconditional approval from the FDA in November 2012 to
initiate its pivotal trial. In July 2012, Sunshine Heart
received CE Mark approval for its C-Pulse System in
Europe. Sunshine Heart is a Delaware corporation headquartered
in Minneapolis with a wholly owned subsidiary in
Australia. The Company has been listed on the NASDAQ Capital
Market since February 2012.
Forward-Looking Statements Certain statements
in this release are forward-looking statements that are based on
management's beliefs, assumptions, expectations, and information
currently available to management. All statements that address
future operating performance, events or developments that we expect
or anticipate will occur in the future are forward-looking
statements, including, without limitation, future clinical trial
activities and results including patient enrollment in trials.
These forward-looking statements are subject to numerous risks and
uncertainties, including, without limitation, the possibility that
our clinical trials do not meet their enrollment goals, meet their
endpoints or otherwise fail, that regulatory authorities do not
accept our application or approve the marketing of the C-Pulse
System, the possibility that we may be unable to raise the funds
necessary for the development and commercialization of our
products, that we may not be able to commercialize our products
successfully in the EU and the other risk factors described under
the caption "Risk Factors" and elsewhere in our filings with the
SEC. You should not place undue reliance on forward-looking
statements because they speak only as of the date when made and may
turn out to be inaccurate. We do not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise. We may
not actually achieve the plans, projections or expectations
disclosed in forward-looking statements, and actual results,
developments or events could differ materially from those disclosed
in the forward-looking statements.
CONTACT: Investor:
Laura Forman
Blueprint Life Science Group
T: +1-415-375-3340
Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200
Media:
David Schull
Russo Partners
T: +1-212-845-4271
Andreas Marathis
Russo Partners
T: +1-212-845-4235
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024